Active Years Wellness
MedCity News Healthcare technology news, life science current events
- Pelago Unveils New Behavioral Health Platform for Substance Use, Mental Health and Behavioral Addiction Careby Marissa Plescia on 22.09.2026 at 23:23
Pelago launched a behavioral health platform that integrates substance use, mental health and behavioral addiction care, using AI-powered triage to connect patients with appropriate treatment. The post Pelago Unveils New Behavioral Health Platform for Substance Use, Mental Health and Behavioral Addiction Care appeared first on MedCity News.
- How is Oracle Health’s Nurse AI Agent Different?by Zoe Cunniffe on 22.09.2026 at 20:44
The Oracle Health Clinical AI Agent is unique in the way it’s embedded directly in the Oracle Health Foundation EHR, making it easier for nurses who don’t have to shift between tools used for separate tasks. The post How is Oracle Health’s Nurse AI Agent Different? appeared first on MedCity News.
- Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Medsby Frank Vinluan on 22.09.2026 at 19:58
Amgen’s dazodalibep led to statistically significant and clinically meaningful results, according to preliminary Phase 3 results in Sjögren’s disease. This fusion protein could compete against a Novartis antibody under an FDA review that could make it the first Sjögren’s therapy. The post Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds appeared first on MedCity News.
- AI Workers Need a Probation Period, Not Just a Pilotby Jost-Vincent Steiskal on 22.09.2026 at 13:06
Healthcare leaders know how to test software. We don’t yet have a shared playbook for onboarding agents expected to do a job end to end. That is the gap a probation period is meant to fill. The post AI Workers Need a Probation Period, Not Just a Pilot appeared first on MedCity News.
- Radiopharmaceutical Dealmaking Continues With Telix’s $1.65B ITM Acquisitionby Frank Vinluan on 21.09.2026 at 20:36
Telix Pharmaceuticals is acquiring Isotope Technologies Munich, or ITM, in a $1.65 billion stock deal that will create a radiopharmaceuticals company with greater global scale. ITM’s lead pipeline asset is in late-stage development for a type of gastrointestinal cancer, where it could compete against Novartis and Curium Pharma products. The post Radiopharmaceutical Dealmaking Continues With Telix’s $1.65B ITM Acquisition appeared first on MedCity News.
- Array Behavioral Care Unveils New Triage Modelby Marissa Plescia on 21.09.2026 at 19:44
Array Behavioral Care launched a new service to help providers assess patients with urgent behavioral health needs and connect them to appropriate care. The post Array Behavioral Care Unveils New Triage Model appeared first on MedCity News.
- How AI Is Transforming Clinical Documentation at Intermountain Healthby Zoe Cunniffe on 21.09.2026 at 17:20
Since implementing AI clinical documentation improvement (CDI) tools, Intermountain has seen a 22% point increase in inpatient chart completion during or immediately after rounds. The post How AI Is Transforming Clinical Documentation at Intermountain Health appeared first on MedCity News.
- The Nurse Is Health Care’s Most Underpriced Founderby Beth A. Brooks and Dan Weberg on 21.09.2026 at 13:31
They see the problem first, build the fix, and decide whether it is ever adopted. The market has trained them to hide the one credential that de-risks the deal. The post The Nurse Is Health Care’s Most Underpriced Founder appeared first on MedCity News.
- Electra’s Upsized IPO Lands $350M for New Class of Precision Immunology Drugsby Frank Vinluan on 20.09.2026 at 22:22
Electra Therapeutics’ IPO cash will support a potential first-in-class drug whose lead indication is a rare hyperinflammatory disorder with no FDA-approved treatments. Meanwhile, clinical-stage biotechs Marea Therapeutics and Sensorion revealed their respective plans to enter the U.S. public markets. The post Electra’s Upsized IPO Lands $350M for New Class of Precision Immunology Drugs appeared first on MedCity News.
- Angle Health Raises $600M to Grow Employer Health Benefits Platformby Marissa Plescia on 20.09.2026 at 21:48
Angle Health’s funding round was led by Vitruvian Partners, with participation from Town Hall Ventures, Blumberg Capital, Portage Ventures, PruVen Capital and Y Combinator. The post Angle Health Raises $600M to Grow Employer Health Benefits Platform appeared first on MedCity News.
- RFK Jr. Overhauls USPSTF Leadership: 5 Things to Knowby Katie Adams on 20.09.2026 at 14:33
HHS Secretary Robert F. Kennedy Jr. named eight new members to the U.S. Preventive Services Task Force this week, completing the 16-seat panel amid ongoing tension over its leadership. The post RFK Jr. Overhauls USPSTF Leadership: 5 Things to Know appeared first on MedCity News.
- Two Years After the Change Healthcare Cyberattack, Healthcare Still Has a Clearinghouse Redundancy Problemby Nihal Titan on 20.09.2026 at 13:45
What happened was not just a cybersecurity failure, it was an infrastructure failure. The post Two Years After the Change Healthcare Cyberattack, Healthcare Still Has a Clearinghouse Redundancy Problem appeared first on MedCity News.
- The Trials Were Always There — Patients Just Couldn’t Find Themby Yuchen Gan on 20.09.2026 at 13:17
This structural problem calls for a structural solution, requiring no new science, regulation, or data. The post The Trials Were Always There — Patients Just Couldn’t Find Them appeared first on MedCity News.
- Ayble Health Secures $16M for Virtual Digestive Health Clinicby Marissa Plescia on 18.09.2026 at 21:32
Ayble Health’s Series A round was led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx and Accomplice. The post Ayble Health Secures $16M for Virtual Digestive Health Clinic appeared first on MedCity News.
- Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippoby Frank Vinluan on 18.09.2026 at 19:38
Ultragenyx Pharmaceutical’s Fayuvi is now the first FDA-approved therapy for the underlying cause of Sanfilippo syndrome type A, an ultra-rare inherited neurological disorder. It’s the second approved gene therapy for Ultragenyx, which specializes in rare disease medicines. The post Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo appeared first on MedCity News.














